A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
